Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Moxisylyte→

Moxisylyte PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
54-32-0
Molecular formula
C16H25NO3
Molecular weight
279.38 g/mol
Drug class
Selective alpha-1 adrenergic receptor antagonistperipheral vasodilator
Mechanism of action
Antagonises postsynaptic alpha-1 adrenoceptors, particularly alpha-1A receptors, reducing catecholamine-mediated vascular smooth-muscle contraction and promoting peripheral vasodilation.
Indications / reported uses
  • Historically used for peripheral circulatory disorders including Raynaud’s phenomenon in countries where authorised.
  • Topical ophthalmic use has been described to reverse sympathomimetic-induced mydriasis; formulation and authorisation are jurisdiction-specific.

Sources: https://meshb.nlm.nih.gov/record/ui?ui=D013948 · https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12306 · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Selective alpha-1 adrenergic receptor antagonist; peripheral vasodilator

Mechanism of action

Antagonises postsynaptic alpha-1 adrenoceptors, particularly alpha-1A receptors, reducing catecholamine-mediated vascular smooth-muscle contraction and promoting peripheral vasodilation.

General use cases

  • Historically used for peripheral circulatory disorders including Raynaud’s phenomenon in countries where authorised.
  • Topical ophthalmic use has been described to reverse sympathomimetic-induced mydriasis; formulation and authorisation are jurisdiction-specific.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Moxisylyte PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Moxisylyte Permitted Daily Exposure (PDE) report (the Moxisylyte PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Moxisylyte Occupational Exposure Limit (OEL) report (the Moxisylyte OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.